BMS CEO Giovanni Caforio (File photo/AP)
A $6B CVR goes pfffft as the game clock runs out on a New Year's deadline for Bristol Myers' liso-cel application
The last seconds of 2020 have ticked away, draining the last of the sand in the hour glass along with any remaining hopes in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.